<--- Back to Details
First PageDocument Content
Mucopolysaccharidosis / Infectious diseases / Sleep disorders / Aging-associated diseases / Lysosomal storage disease / Infection / Hydrocephalus / Sly syndrome / Sleep apnea / Health / Rare diseases / Syndromes
Date: 2011-09-13 15:29:33
Mucopolysaccharidosis
Infectious diseases
Sleep disorders
Aging-associated diseases
Lysosomal storage disease
Infection
Hydrocephalus
Sly syndrome
Sleep apnea
Health
Rare diseases
Syndromes

13465 MPS VII v5:Layout 1

Add to Reading List

Source URL: www.mpssociety.org

Download Document from Source Website

File Size: 208,68 KB

Share Document on Facebook

Similar Documents

Implantação de um protocolo laboratorial para o diagnóstico de Mucopolissacaridoses VI e VII* Evaluation of a laboratorial protocol for Mucopolysaccharidosis VI and VII Gustavo Monteiro VIANA1; Camila de Britto Ponte

Implantação de um protocolo laboratorial para o diagnóstico de Mucopolissacaridoses VI e VII* Evaluation of a laboratorial protocol for Mucopolysaccharidosis VI and VII Gustavo Monteiro VIANA1; Camila de Britto Ponte

DocID: 1v8Z4 - View Document

What is  HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

MUCOPOLYSACCHARIDOSES  Rare Diseases Unit of the Finnish Association of People with Physical Disabilities  Support for this guide was provided by Genzyme.

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

May 27, 2014  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document

Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final

Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final

DocID: 19Qom - View Document